News & Events
< Back to News Overview
CogState Signs Agreement for Phase IV Trial with Pfizer
21 / 08 / 2007
Key points:
Phase IV trial conducted by Pfizer throughout Europe will use CogState technology and services
Cognition, as measured by change in CogState score, is the primary endpoint for the trial
CogState Ltd (ASX:CGS) announced today that it has signed an agreement with Pfizer for the use of CogState's cognitive testing technology, and associated services, in a Phase IV trial to be conducted in more than 20 sites throughout Europe.
The trial will investigate the benefits of growth hormone replacement therapy in patients suffering from severe growth hormone deficiency after traumatic brain injury, and will focus on the potential effects on cognitive function.
The primary endpoint of the trial will be the change from baseline in CogState scores after 36 weeks.
Mr Brad O'Connor, Chief Executive Officer of CogState, said: "It is pleasing to see our customers relying on our scientific expertise and technology solutions to answer primary study questions. We are particularly well suited for use in this trial because of our experience and scientific expertise with respect to brain injury. Further, with CogState's real time data management systems, we are well placed to manage the data collected in multi-centre studies, conducted anywhere in the world."
Mr O'Connor added: "Coming on the back of recent contracts with Merck, GalxoSmithKline and AstraZeneca, this contract is particularly encouraging and indicates an increasing level of demand for CogState's technology and associated services."
Phase IV trial conducted by Pfizer throughout Europe will use CogState technology and services
Cognition, as measured by change in CogState score, is the primary endpoint for the trial
CogState Ltd (ASX:CGS) announced today that it has signed an agreement with Pfizer for the use of CogState's cognitive testing technology, and associated services, in a Phase IV trial to be conducted in more than 20 sites throughout Europe.
The trial will investigate the benefits of growth hormone replacement therapy in patients suffering from severe growth hormone deficiency after traumatic brain injury, and will focus on the potential effects on cognitive function.
The primary endpoint of the trial will be the change from baseline in CogState scores after 36 weeks.
Mr Brad O'Connor, Chief Executive Officer of CogState, said: "It is pleasing to see our customers relying on our scientific expertise and technology solutions to answer primary study questions. We are particularly well suited for use in this trial because of our experience and scientific expertise with respect to brain injury. Further, with CogState's real time data management systems, we are well placed to manage the data collected in multi-centre studies, conducted anywhere in the world."
Mr O'Connor added: "Coming on the back of recent contracts with Merck, GalxoSmithKline and AstraZeneca, this contract is particularly encouraging and indicates an increasing level of demand for CogState's technology and associated services."